Compare HZO & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HZO | ASMB |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.9M | 553.6M |
| IPO Year | 1998 | 2010 |
| Metric | HZO | ASMB |
|---|---|---|
| Price | $24.83 | $33.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $34.00 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 300.2K | 139.2K |
| Earning Date | 01-22-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,309,288,000.00 | $37,191,000.00 |
| Revenue This Year | $2.11 | $33.33 |
| Revenue Next Year | $4.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.30 |
| 52 Week Low | $16.85 | $7.75 |
| 52 Week High | $33.28 | $39.71 |
| Indicator | HZO | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 48.81 |
| Support Level | $24.28 | $31.51 |
| Resistance Level | $25.49 | $38.99 |
| Average True Range (ATR) | 0.99 | 2.15 |
| MACD | -0.01 | -0.32 |
| Stochastic Oscillator | 34.45 | 33.29 |
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S and international market.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.